menu
    • menu

    Company profile for Xalud Therapeutics

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    a non-viral gene therapy platform to treat pathologic inflammation through immune modulation. The company is harnessing the power of interleukin-10 (IL-10), a potent cytokine that acts as a master regulator for multiple inflammatory pathways, to address the root cause of inflammation and subsequently restore homeostasis in the immune system. Xalud’s lead product candidate, XT-150, is a locally injectable plasmid DNA gene t...
    a non-viral gene therapy platform to treat pathologic inflammation through immune modulation. The company is harnessing the power of interleukin-10 (IL-10), a potent cytokine that acts as a master regulator for multiple inflammatory pathways, to address the root cause of inflammation and subsequently restore homeostasis in the immune system. Xalud’s lead product candidate, XT-150, is a locally injectable plasmid DNA gene therapy expressing IL-10 to addresses pathologic inflammation and pain.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Xalud TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    40 West 57th Street, Suite 1810 New York, NY 10019
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.xaludthera.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Natural Products Expo

    Natural Products Expo

    Not Confirmed

    envelop Contact Supplier

    Natural Products Expo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Xalud Therapeutics prioritizes gene therapies, with ALS
    Xalud Therapeutics prioritizes gene therapies, with ALS

    12 Jun 2023

    // Kyle LaHucik ENDPTS

    https://endpts.com/xalud-therapeutics-prioritizes-gene-therapies-with-als-now-the-focus-and-osteoarthritis-on-partner-path/

    Kyle LaHucik ENDPTS
    12 Jun 2023
    Share Share
    Xalud Therapeutics Presents Clinical Data on XT-150 in Knee Osteoarthritis
    Xalud Therapeutics Presents Clinical Data on XT-150 in Knee Osteoarthritis

    20 Mar 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/03/20/2630198/0/en/Xalud-Therapeutics-Presents-Clinical-Data-on-XT-150-in-Knee-Osteoarthritis-at-the-2023-Osteoarthritis-Research-Society-International-World-Congress.html

    GLOBENEWSWIRE
    20 Mar 2023
    Share Share
    Xalud Therapeutics CEO to Participate in Two Gene Therapy
    Xalud Therapeutics CEO to Participate in Two Gene Therapy

    06 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/06/2456643/0/en/Xalud-Therapeutics-CEO-to-Participate-in-Two-Gene-Therapy-Focused-Panels-at-BIO-International-Convention-2022.html

    GLOBENEWSWIRE
    06 Jun 2022
    Share Share
    Xalud Tx Doses First Patient in Phase 2a Trial of XT-150 for Osteoarthritis Pain
    Xalud Tx Doses First Patient in Phase 2a Trial of XT-150 for Osteoarthritis Pain

    02 Mar 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220302005316/en

    BUSINESSWIRE
    02 Mar 2022
    Share Share
    Xalud Receives FDA FTD for XT-150 in Pain Associated with Osteoarthritis
    Xalud Receives FDA FTD for XT-150 in Pain Associated with Osteoarthritis

    17 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211217005057/en

    BUSINESSWIRE
    17 Dec 2021
    Share Share
    Immunocore's bispecific gets speedy review with FDA, EMA; Xalud grabs $30M
    Immunocore's bispecific gets speedy review with FDA, EMA; Xalud grabs $30M

    24 Aug 2021

    // Paul Schloesser\nMax Gelman\nAmber Tong ENDPTS

    https://endpts.com/immunocores-bispecific-lands-speedy-review-with-fda-ema-low-profile-gene-therapy-player-grabs-30m/

    Paul Schloesser\nMax Gelman\nAmber Tong ENDPTS
    24 Aug 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search